Avacta Announces Preclinical and Translational Presentations of pre|CISION Platform Candidates at AACR 2026

Biopharmaceutical company Avacta to showcase tumor-activated oncology delivery platform at major cancer research conference.

Mar. 17, 2026 at 8:06am

Got story updates? Submit your updates here. ›

Avacta Therapeutics, a clinical-stage biopharmaceutical company, announced it will deliver two presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego. The presentations will focus on Avacta's pre|CISION platform, a tumor-activated oncology delivery system designed to concentrate highly potent cancer payloads in the tumor microenvironment while sparing normal tissues.

Why it matters

Avacta's pre|CISION platform represents a novel approach to cancer treatment that aims to improve the therapeutic index of highly potent payloads by selectively activating them within the tumor. This could lead to more effective and better-tolerated cancer therapies. The presentations at AACR 2026 will provide important preclinical and translational data on the platform's capabilities.

The details

The first presentation will focus on AVA6103, a FAP-enabled pre|CISION peptide-drug conjugate that delivers sustained release of the potent anticancer agent exatecan in the tumor microenvironment. The second presentation will cover the characterization and translational development of novel pre|CISION technology compounds that deliver complementary dual payloads to the tumor following FAP cleavage.

  • The AACR Annual Meeting 2026 will take place from April 17-22, 2026 in San Diego, California.
  • The two Avacta presentations are scheduled for Tuesday, April 21, 2026 from 2:00-5:00pm PDT.

The players

Avacta Therapeutics

A clinical-stage biopharmaceutical company developing the pre|CISION tumor-activated oncology delivery platform.

American Association for Cancer Research (AACR)

A professional organization dedicated to advancing cancer research and discovery.

Got photos? Submit your photos here. ›

The takeaway

Avacta's presentations at AACR 2026 will showcase the potential of its pre|CISION platform to improve the therapeutic index of potent cancer therapies by selectively activating them within the tumor microenvironment. This innovative approach could lead to more effective and better-tolerated treatments for cancer patients.